As of July 3, 2026, we had approximately 2.5 million shares available for issuance under our 2021 Omnibus Incentive Plan (the “2021 Plan”) and approximately 0.9 million shares available for issuance under our 2021 Employee Stock Purchase Plan (the “Employee Stock Purchase Plan”). Under the 2021 Plan, we have the ability to issue incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), unrestricted stock awards, stock units (including restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”)), performance awards, cash awards, and other share-based awards to employees, directors, consultants and advisors. The ISOs and NSOs must be granted at an exercise price, and the SARs must be granted at a base value, per share of not less than 100% of the closing price of a share of our common stock on the date of grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported) (110% in the case of certain ISOs). Certain of the share-based awards granted and outstanding as of July 3, 2026 are subject to accelerated vesting upon a change in control of the Company.

Aside from the equity plans described above, we also grant incentive stock units (“ISUs”) to certain of our international employees which typically vest over three years and for which the fair value is determined by our underlying stock price, which are classified as liabilities and settled in cash upon vesting.

As of July 3, 2026 and October 3, 2025, the fair value of outstanding ISUs was $10.1 million and $5.1 million, respectively, and the associated accrued compensation liability was $6.1 million and $3.7 million, respectively. During the three and nine months ended July 3, 2026, we recorded an expense for ISU awards of $2.7 million and $5.9 million, respectively. During the three and nine months ended July 4, 2025, we recorded an expense for ISU awards of $1.8 million and $3.0 million, respectively. These expenses are not included in the share-based compensation expense totals below.


	Three Months Ended				Nine Months Ended
	July 3, 2026		July 4, 2025		July 3, 2026		July 4, 2025
Cost of revenue	$	2,324	$	1,728	$	6,920	$	6,376
Research and development	7,671		7,109		25,628		25,235
Selling, general and administrative	11,102		8,469		33,325		29,982
Total share-based compensation expense	$	21,097	$	17,306	$	65,873	$	61,593

As of July 3, 2026, the total unrecognized compensation costs related to RSUs and PRSUs was $119.3 million, which we expect to recognize over a weighted-average period of 1.9 years. As of July 3, 2026, total unrecognized compensation cost related to our Employee Stock Purchase Plan was $1.9 million.


	Number of shares (in thousands)	Weighted- Average Grant Date Fair Value
Balance as of October 3, 2025	1,419	$	97.19
Granted	539	$	171.15
Performance-based adjustment (1)	201	$	85.93
Vested and released	(856)	$	83.73
Forfeited, canceled or expired	(68)	$	114.54
Balance as of July 3, 2026	1,235	$	136.00

(1) The amount shown represents performance adjustments for performance-based awards. These were granted in prior fiscal years and vested during the nine months ended July 3, 2026 based on the Company’s achievement of adjusted earnings per share and total shareholder return performance conditions.

We granted 107,977 market-based PRSUs during the nine months ended July 3, 2026, at a weighted average grant date fair value of $215.59 per share. Recipients may earn between 0% and 200% of the target number of shares based on the Company’s achievement of total stockholder return in comparison to a peer group of companies in the PHLX Semiconductor Sector Index (^SOX) over a period of approximately three years. The fair value of the awards was estimated using a Monte Carlo simulation and compensation expense is recognized ratably over the service period based on the grant date fair value of the awards subject to the market condition. The expected volatility of the Company’s common stock was estimated based on the historical average volatility rate over the three-year period. The dividend yield assumption was based on historical and anticipated dividend payouts. The risk-free rate assumption was based on observed interest rates consistent with the three-year measurement period.


	Nine Months Ended
	July 3, 2026
Weighted-average grant date stock price	$	151.20
Weighted-average stock price at the start of the performance period	$	128.76
Weighted-average risk free interest rate	3.5%
Weighted-average years to maturity	2.9
Weighted-average expected volatility rate	41.7%
Weighted-average expected dividend yield	—